Viropro Wishes to Update Investors and the Investment Community on Its Operations
21 Januar 2011 - 1:10PM
Business Wire
Viropro (PK: VPRO) wishes to update investors and
the investment community on its operations. Recent headlines
on the Company have attracted considerable attention and management
wishes to outline the following:
- Financial Statements of the Company
have been audited for the period ending December 31, 2009 and
quarterlies have been reviewed until March 31, 2010.
- Company intends to file updated
unaudited financial statements on the Pink Sheet; those statements
will be consolidated and will include those of its 100% owned
subsidiaries Biologics Process Development Inc. of San Diego and
Viropro International of Montreal, QC. Filing is scheduled for the
end of February.
- Once the financials are filed, Company
will request that auditing be conducted which in turn will allow
Company to solicit better listing opportunities.
- A 25% reduction in the number of fully
diluted outstanding shares has just been operated. A reserve of
108,015,823 shares for the conversion of a debenture was cancelled
as said debenture was bought back.
- Company is requesting to be included in
the FAST program whereby all stock transactions would be treated
electronically.
- Company is currently updating its
website for further references.
Viropro’s business plan calls for a one stop shop in
Biotechnology Contractual Development and Manufacturing Services
and to do so, acquisitions will be necessary. Said business plan
will not be made available to the public as potential acquisitions
are clearly stated. Viropro’s entire management is keen on
implementing said plan and is highly motivated towards reaching
that goal.
About Viropro, Inc.:
Viropro, Inc. conducts its operations through its subsidiaries
Viropro International, Inc. and Biologics Process Development, Inc.
The Company's principal objective and mission is to "make biotech
drugs for its clients, efficiently and economically." Towards this
end, the Company specializes in the use of its Intellectual
Property and high-yield manufacturing process technologies, for
industrial-scale production of biopharmaceutical drugs for its
clients that serve global markets, with unmet medical- and/or
market needs (www.viropro.com).
About Biologics Process Development, Inc.:
Biologics Process Development, Inc. (BPD), located in Poway (San
Diego area), California, has been providing contract laboratory
services to the biotechnology and biopharmaceutical industries for
fourteen years. The range of services includes molecular biology,
cell culture, fermentation, protein purification, frozen storage,
process scale-up and consulting services. BPD has an impressive
list of clients that range from university laboratories to
well-known biotechnology and biopharmaceutical companies.
(www.biologicspd.com)
About Intas Biopharmaceuticals Limited:
Intas Biopharmaceuticals Limited is a fully integrated
biopharmaceutical company based out of Ahmedabad, Gujarat, India.
Since launch of biotechnology operations in May 2000, Research
& Development (R&D) and Manufacturing of Biopharmaceutical
products with a special focus on Oncology (Cancer) are the major
thrust areas for the company. Intas Biopharmaceuticals is India's
first and only biopharmaceutical company to receive European Union
-Good Manufacturing Practice (EU-GMP) certification for its
manufacturing facility. (www.intasbiopharma.co.in)
Viropro Inc. Safe Harbor Statement
Except for any historic information contained herein, the
matters discussed in this press release contain forward-looking
statements that involve risks and uncertainties, which are subject
to section 27A of the Securities Act of 1933 and section 21E of the
Exchange Act of 1934, and are subject to safe harbor created by
these sections. Any statements that express or involve discussions
with respect to predictions, beliefs, plans, projections,
objectives, goals, assumptions of future events or performances are
not statements of historical fact and may be "forward-looking
statements". Forward-looking statements in this release may be
identified through the use of such words as "expects",
"anticipates", "estimates", "believes", or statements indicating
certain actions "may", "could", or "might" occur. Actual results,
performance or achievements could differ materially from those
anticipated in such forward-looking statements, which involve
numerous risks and uncertainties, including the Company's ability
to market its products and services in a competitive environment as
well as other factors.
For more information on Viropro Inc., please visit our website
on www.viropro.com
Viropro (CE) (USOTC:VPRO)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Viropro (CE) (USOTC:VPRO)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
